Amedeo Smart

Free Medical Literature Service

 

Amedeo

Otorhinolaryngology
  Free Subscription

Articles published in
Oral Oncol
    April 2026
  1. HUANG YJ, Fang KC, Tsai MH, Chuang HC, et al
    Swallowing-related outcomes and organ-at-risk dosimetry after proton versus photon radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2026;175:107906.
    >> Share

  2. CRACCHIOLO JR, Kavanagh F, Starc MT, Scholfield D, et al
    Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.
    Oral Oncol. 2026;175:107882.
    >> Share

  3. PARK H, Kim BR, Yoo JH, Kim SW, et al
    Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.
    Oral Oncol. 2026;175:107912.
    >> Share

  4. MANFUSO A, Cirignaco G, Cocis S, Volpe F, et al
    Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores.
    Oral Oncol. 2026;175:107916.
    >> Share

  5. NGO DQ, Le DT, Ngo QX, Le QV, et al
    Surgical outcomes of modified versus conventional transoral endoscopic thyroidectomy vestibular approach for papillary thyroid carcinoma.
    Oral Oncol. 2026;175:107908.
    >> Share

    March 2026
  6. TOPKAN E, Selek U
    Comment on low-dose fractionated radiotherapy during induction chemotherapy for node-positive locoregionally advanced nasopharyngeal carcinoma: a randomized phase II trial.
    Oral Oncol. 2026;176:107940.
    >> Share

  7. KASAHARA K, Kono T, Sato Y, Okubo K, et al
    Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression.
    Oral Oncol. 2026;176:107938.
    >> Share

  8. KOCH N, Yosefof E, Gleber-Netto FO, Amir I, et al
    Elective neck irradiation does not improve regional control or survival in pT3-T4N0 oral cavity SCC after high-yield neck dissection: A retrospective multicenter analysis.
    Oral Oncol. 2026;176:107946.
    >> Share

  9. LEE SF, Hircock C, Yip PL, Cheo T, et al
    Limitations of quality-of-life assessment and long-term side effects in nasopharyngeal carcinoma: a narrative review.
    Oral Oncol. 2026;176:107935.
    >> Share

  10. JAGADEESHA S, Lamenza F, Upadhaya P, Chung C, et al
    Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107929.
    >> Share

  11. DOU K, Liu D, Shi Y, Qin H, et al
    Can the submandibular gland be preserved during neck dissection in patients with oral squamous cell carcinoma?A systematic review and meta-analysis.
    Oral Oncol. 2026;176:107913.
    >> Share

  12. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Corrigendum to "Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study" [Oral Oncol. 173 (2026) 107851].
    Oral Oncol. 2026 Mar 5:107919. doi: 10.1016/j.oraloncology.2026.107919.
    >> Share

  13. SHIMIZU T, Takahashi H, Tada H, Chikamatsu K, et al
    Integrative analysis of aging-related immune parameters reveals prognostic and immunotherapeutic implications in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107914.
    >> Share

  14. CHU F, Benzi P, Tagliabue M, Mossinelli C, et al
    Rare laryngeal tumors: A retrospective bicentric study on 74 patients and systematic review.
    Oral Oncol. 2026;174:107852.
    >> Share

  15. WOJTERA BP, Beharry A, Salati V, Lambercy K, et al
    Long-term swallowing outcomes following transoral robotic surgery for oropharyngeal cancer - Five years and beyond.
    Oral Oncol. 2026;174:107876.
    >> Share

    February 2026
  16. ZHAO ZY, He SQ, Liu GY, Lv SH, et al
    Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
    Oral Oncol. 2026;175:107907.
    >> Share

  17. NTOUKAS SM, Mohamad N, Boparai R, Dennett L, et al
    Effects of exercise on health-related fitness and patient-reported outcomes in survivors of head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;175:107902.
    >> Share

  18. BHATI M, Bagchi P, Pawar P, Baviskar P, et al
    Aberrant lateral position of external carotid artery, a surgical pitfall during neck dissection.
    Oral Oncol. 2026;175:107905.
    >> Share

  19. HOLGADO A, Llansana A, Vazquez C, Gallego O, et al
    Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy.
    Oral Oncol. 2026;175:107903.
    >> Share

  20. ECONOMOPOULOU P, Pouliakis A, Kyprianou M, Pantazopoulos A, et al
    An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
    Oral Oncol. 2026;175:107900.
    >> Share

  21. MARGONI A, Papavassiliou KA, Papavassiliou AG
    From heterogeneity to molecular stratification: A multiplex genomic panel for tailored therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107904.
    >> Share

  22. LI C, Xiao X, Jiang H, Li B, et al
    Comparable survival after lobectomy and total thyroidectomy for T3b differentiated thyroid carcinoma: A population-based study.
    Oral Oncol. 2026;175:107891.
    >> Share

  23. XIN Y, Yang L, Liu C, Li D, et al
    Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107887.
    >> Share

  24. FAN M, Yin Q, Li L, Lian Q, et al
    Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial.
    Oral Oncol. 2026;175:107888.
    >> Share

  25. BENITES C, White C, Balaguru L, Gonghao L, et al
    Does discharge location following head and neck cancer surgery affect quality outcomes?
    Oral Oncol. 2026;175:107879.
    >> Share

  26. SINGH SP, Prasad S, Dean PM, Kujur AL, et al
    Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.
    Oral Oncol. 2026;174:107862.
    >> Share

  27. ZHANG L
    Comment on "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery".
    Oral Oncol. 2026;174:107881.
    >> Share

  28. ROY P, Weber MB, Gupta R, Kakkar A, et al
    The prognostic significance of the 'Worst Pattern of Invasion' in oral cancers-an international collaborative multicentre analysis.
    Oral Oncol. 2026;174:107874.
    >> Share

  29. TAKAHASHI Y, Bell D, Corona A, Su SY, et al
    Establishment of novel stable human sinonasal NUT carcinoma cell lines.
    Oral Oncol. 2026;173:107828.
    >> Share

    January 2026
  30. HACK S, Karni RJ, Maniaci A, Fundakowski CE, et al
    Evaluation of large language models as decision support tools for head and neck cancer management: A blinded multidisciplinary simulation study.
    Oral Oncol. 2026;174:107877.
    >> Share

  31. WANG N, Gao H, Yu SX, Fan J, et al
    The first report of contralateral parapharyngeal space metastasis of papillary thyroid carcinoma: report of a case.
    Oral Oncol. 2026;174:107865.
    >> Share

  32. ZHONG J, Chen H, Yan Z, Xu H, et al
    Refinement of N category in version-nine of AJCC/UICC TNM staging system for nasopharyngeal carcinoma based on the international consensus recommendations for diagnosing extranodal extension.
    Oral Oncol. 2026;174:107866.
    >> Share

  33. ALMEIDA ND, Schrand TV, Sullivan D, Yu H, et al
    Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;174:107859.
    >> Share

  34. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
    Oral Oncol. 2026;174:107858.
    >> Share

  35. CHENG C, Zhang J
    Advancing methodological rigor in exercise oncology trials for head and neck cancer.
    Oral Oncol. 2026;173:107857.
    >> Share

  36. CAROSI F, Demurtas S, Ciarfella A, Orlandi E, et al
    Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease.
    Oral Oncol. 2026;173:107853.
    >> Share

  37. WANG W, Lou Y
    From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma.
    Oral Oncol. 2026;173:107854.
    >> Share

  38. SOBY S, Mortensen D, Gothelf A, Gyldenkerne N, et al
    Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.
    Oral Oncol. 2026;173:107849.
    >> Share

  39. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study.
    Oral Oncol. 2026;173:107851.
    >> Share

  40. MARGONI A, Papavassiliou KA, Papavassiliou AG
    Harnessing TP53 mutational status to enhance prognostic precision and therapeutic effectiveness in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;173:107846.
    >> Share

  41. WU WJ, An PG, Zhang ZQ, Shen LH, et al
    Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial.
    Oral Oncol. 2026;172:107809.
    >> Share

  42. NIU S, Ding J, Chen H, Zhu Z, et al
    Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2026;173:107845.
    >> Share

    December 2025
  43. XIAO G, Ning L, Chen L, Zhang S, et al
    Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial.
    Oral Oncol. 2025;173:107844.
    >> Share

  44. JAKOBSEN KK, H Rasmussen J, Melchiors J, Agander TK, et al
    Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis.
    Oral Oncol. 2025;173:107843.
    >> Share

  45. LECHIEN JR, Paleri V, Baudouin R, Brunet A, et al
    European surgical guidelines: transoral robotic surgery for head and neck cancers.
    Oral Oncol. 2025;173:107826.
    >> Share

  46. CHAUDHRY M, Elfar A, Rowsey K, Neel A, et al
    Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research.
    Oral Oncol. 2025;173:107840.
    >> Share

  47. ZHANG M, Song J, Yuan Y, Cao X, et al
    Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107841.
    >> Share

  48. PARK SE, Hong SH, Park JO, Kim SY, et al
    Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy.
    Oral Oncol. 2025;173:107827.
    >> Share

  49. THIAGARAJAN S, Rukmangathan T, Sharma D, Kakade A, et al
    Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study.
    Oral Oncol. 2025;173:107838.
    >> Share

  50. LIU Q, Wei JN, Zhou JY, Zhang CR, et al
    Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107825.
    >> Share

  51. ZOU C
    Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;172:107705.
    >> Share

  52. CHOW VL, Ho VW, Lo AS
    Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer.
    Oral Oncol. 2025;172:107819.
    >> Share

  53. YOON HN, Kim JH, Gu D, Lee J, et al
    Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;172:107814.
    >> Share

  54. SHAIKH MH, Gazala W, Zeng C, Naimi MF, et al
    NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer.
    Oral Oncol. 2025;172:107815.
    >> Share

  55. HACK S, Attal R, Geva K, Farzad A, et al
    Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
    Oral Oncol. 2025;172:107813.
    >> Share

  56. BARAN E, Lee M, Kamalraj P, Karam I, et al
    Cancer stage documentation and accuracy: Single-center retrospective study on oropharyngeal cancers.
    Oral Oncol. 2025;171:107795.
    >> Share

  57. CHELVARAJAH RC, Huang SH, Su J, Gete M, et al
    Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma.
    Oral Oncol. 2025;171:107794.
    >> Share

  58. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
    Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
    Oral Oncol. 2025;171:107792.
    >> Share

  59. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
    Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
    Oral Oncol. 2025;171:107768.
    >> Share

    November 2025
  60. LECHIEN JR
    Learning process of transoral robotic surgery for head and neck cancers: a scoping review.
    Oral Oncol. 2025;171:107788.
    >> Share

  61. LI M, Zhou Y, Cai M
    Letter to the Editor: A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;171:107784.
    >> Share

  62. OKURA M, Yamakawa N, Otsuru M, Hasegawa T, et al
    T4a classification for oral cancer using mandibular canal invasion instead of bone marrow invasion in the TNM staging system.
    Oral Oncol. 2025;171:107771.
    >> Share

  63. DOERFLER R, Chen J, Kim C, Smith JD, et al
    Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer.
    Oral Oncol. 2025;171:107742.
    >> Share

  64. DIEZ-FRAILE A, Pottel L, Lamoral P, De Backer T, et al
    Age and surgical complexity outperform preoperative Geriatric-8 for 30-day major complications in older head and neck cancer.
    Oral Oncol. 2025;171:107774.
    >> Share

  65. VAN LOOCKE P, Beuselinck B, Meulemans J, Nuyts S, et al
    Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study.
    Oral Oncol. 2025;171:107772.
    >> Share

  66. TIRELLI G, Boscolo-Rizzo P
    Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1.
    Oral Oncol. 2025;171:107770.
    >> Share

  67. MASO V, Lechien JR, Gengler I, Chiesa-Estomba C, et al
    Management of head and neck cancer around the world: an international survey by the world ear, nose, and throat federation.
    Oral Oncol. 2025;171:107766.
    >> Share

  68. WILLIAMS MM, Hanna GJ, Sethi RK, Rettig EM, et al
    Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders.
    Oral Oncol. 2025;170:107761.
    >> Share

  69. LI R, Ma S, Tang T, Zhao Y, et al
    Prognostic impact and risk factors of level IV/V lymph nodes metastasis in laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107758.
    >> Share

  70. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
    Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
    Oral Oncol. 2025;171:107767.
    >> Share

    October 2025
  71. BERTIN B, Kowalski LP, Matos LL
    The low evidence to treat elderly patients with head and neck cancer.
    Oral Oncol. 2025;171:107764.
    >> Share

  72. XIANG N, Li W
    Re: "Patterns of care in de?novo oligo?metastatic and oligo?recurrent head and neck cancers: A HNCIG survey" (Oral oncology).
    Oral Oncol. 2025;171:107749.
    >> Share

  73. DAS R, Misra SR, Mohapatra SSG
    Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
    Oral Oncol. 2025;170:107752.
    >> Share

  74. LIANG H, Guo Y
    Comment on "Massive nasal bleeding in nasopharyngeal carcinoma": Risk stratification and clinical implications.
    Oral Oncol. 2025;170:107755.
    >> Share

  75. HELOU V, Abdul-Rahman NH, Loo SK, Gao SJ, et al
    Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;170:107760.
    >> Share

  76. WANG Q, Yang Q, Wang Z, Duan X, et al
    Efficacy of primary lesion re-irradiation in nasopharyngeal carcinoma with synchronous recurrence and distant metastasis.
    Oral Oncol. 2025;170:107743.
    >> Share

  77. KANG SK, Brooks E, Wolk R, Siriruchatanon M, et al
    Assessing liquid biopsy tests for the detection of head and neck squamous cell carcinoma: an umbrella review.
    Oral Oncol. 2025;170:107535.
    >> Share

  78. BOIDE A, Glasmacher AR, Wurschi G, Tews AM, et al
    Fear of cancer recurrence in adults with p16-positive head and neck cancer after radiotherapy - Results from a multicenter cross-sectional observational study.
    Oral Oncol. 2025;170:107757.
    >> Share

  79. HONG MH, Lee S, Kim CG, Son W, et al
    A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107745.
    >> Share

  80. JEYARAJ G
    Commentary on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025 Oct 10:107741. doi: 10.1016/j.oraloncology.2025.107741.
    >> Share

  81. MARUDHUPANDI T
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107746.
    >> Share

  82. LI Y, Tong S, Tian J, You X, et al
    Comment on: "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial".
    Oral Oncol. 2025;170:107729.
    >> Share

  83. LI S, Garb BF, Qin T, Soppe SE, et al
    Tumor subtype classification tool for HPV-associated head and neck cancers.
    Oral Oncol. 2025;170:107726.
    >> Share

  84. SWAIN M, Ghosh-Laskar S, McDowell L, Henson C, et al
    Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
    Oral Oncol. 2025;170:107647.
    >> Share

  85. VARETA JA, Zhang X, Kuhnell D, Hagen MC, et al
    Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing.
    Oral Oncol. 2025;169:107694.
    >> Share

  86. HAGREN A, Sjovall J, Brogardh C, Johansson K, et al
    Head and neck lymphedema after radiotherapy - Prevalence, changes and associated factors - a prospective observational cohort study.
    Oral Oncol. 2025;169:107671.
    >> Share

  87. HINTZE JM, Cleere E, Timon C, Kinsella J, et al
    The lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107625.
    >> Share

  88. SIQUEIRA JM, Heguedusch D, Cunha MT, de Sousa LG, et al
    Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition.
    Oral Oncol. 2025;169:107634.
    >> Share

  89. HOUCINE Y, Kedous S, Kamoun S, Methnani A, et al
    Nasopharyngeal low-grade papillary Adenocarcinoma: A rare entity with diagnostic challenges.
    Oral Oncol. 2025;169:107612.
    >> Share

  90. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    >> Share

  91. MARUDHUPANDI T
    Letter to the Editor: Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;170:107731.
    >> Share

  92. MARUDHUPANDI T
    Letter to the editor: Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107730.
    >> Share

    September 2025
  93. MISRA SR, Das R
    Palliative care integration in head and neck Cancer: Bridging the gap between evidence and practice.
    Oral Oncol. 2025;170:107735.
    >> Share

  94. MISRA SR, Das R, Giri M
    Commentary on "pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial".
    Oral Oncol. 2025;170:107701.
    >> Share

  95. ANNAMALAI A
    Comments on, "Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study".
    Oral Oncol. 2025;170:107716.
    >> Share

  96. ZHANG M
    Comment on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;170:107722.
    >> Share

  97. HUANG S, Liao D, Zhu X, Feng Y, et al
    Advancing oral cancer equity in India novel pathways for screening impact.
    Oral Oncol. 2025;170:107696.
    >> Share

  98. LI M, Zhou Y, Cai M
    Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107725.
    >> Share

  99. MISRA SR, Das R
    Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!
    Oral Oncol. 2025;170:107718.
    >> Share

  100. DUAN Y
    Comments on: Stroke risk after head and neck cancer diagnosis and treatment in a real-world clinical cohort.
    Oral Oncol. 2025;170:107717.
    >> Share

  101. AL MAQRASHI ZAA, Kartolo A, Meyers BM
    Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
    Oral Oncol. 2025;170:107704.
    >> Share

  102. CHENG H, Jiang M, Kim S, Moshiri A, et al
    Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107687.
    >> Share

  103. MISRA SR, Das R
    Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
    Oral Oncol. 2025;169:107692.
    >> Share

  104. SAMUEL M
    Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
    Oral Oncol. 2025;169:107693.
    >> Share

  105. SINDYA J, Rajanathadurai J, Perumal E
    Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107691.
    >> Share

  106. SASIKALA S, Sowmiya A, Usharani N
    Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2025;169:107668.
    >> Share

  107. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    >> Share

  108. VENKATACHALAM DK, Kanimozhi K
    Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107679.
    >> Share

  109. MISRA SR, Das R
    The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
    Oral Oncol. 2025;169:107676.
    >> Share

  110. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    >> Share

  111. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    >> Share

  112. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    >> Share

  113. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    >> Share

  114. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    >> Share

  115. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    >> Share

  116. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    >> Share

  117. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    >> Share

  118. PENG X, Xie Y, Liu Y
    Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
    Oral Oncol. 2025;169:107644.
    >> Share

  119. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
    Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
    Oral Oncol. 2025;169:107607.
    >> Share

  120. DUNN LA, Ho AL, Michel LS, Wong W, et al
    A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;169:107524.
    >> Share

  121. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
    Patterns of referral and outcomes in oropharyngeal cancer management.
    Oral Oncol. 2025;168:107602.
    >> Share

  122. GILI R, Morbini P, Bossi P
    PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
    Oral Oncol. 2025;168:107606.
    >> Share

  123. YANG J, Wu W, Liu J, Li J, et al
    Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;168:107595.
    >> Share

  124. KLEEBAYOON A, Wiwanitkit V
    Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
    Oral Oncol. 2025;169:107645.
    >> Share

  125. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
    Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;169:107599.
    >> Share

    August 2025
  126. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    >> Share

  127. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
    Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
    Oral Oncol. 2025;169:107628.
    >> Share

  128. DAI Y, Li W
    Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
    Oral Oncol. 2025;169:107640.
    >> Share

  129. KANA L, Chamma B, Robinette N, Cramer JD, et al
    Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
    Oral Oncol. 2025;169:107633.
    >> Share

  130. HUANG J, Yan X, Wang S, Huang S, et al
    Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
    Oral Oncol. 2025;169:107639.
    >> Share

  131. CAO J, Han W, Liu Y
    Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;169:107624.
    >> Share

  132. HUANG X, Gu X
    Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;169:107626.
    >> Share

  133. MISRA SR, Das R
    Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
    Oral Oncol. 2025;169:107637.
    >> Share

  134. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
    Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;169:107596.
    >> Share

  135. TANG Y, Jin Q, Gan X
    Comment on "Social health at 5 years after diagnosis of head and neck cancer".
    Oral Oncol. 2025;169:107627.
    >> Share

  136. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
    Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107632.
    >> Share

  137. DAI Y, Li WJ
    Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
    Oral Oncol. 2025;169:107613.
    >> Share

  138. CHEN Y, Yan Y
    Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107614.
    >> Share

  139. LUO R, Wu J, Zhong W, Ai K, et al
    Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107610.
    >> Share

  140. ZHANG J, Liu DM
    Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
    Oral Oncol. 2025;169:107611.
    >> Share

  141. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107604.
    >> Share

  142. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    >> Share

  143. COLAK G, Demir B
    Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107579.
    >> Share

  144. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
    The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
    Oral Oncol. 2025;168:107582.
    >> Share

  145. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
    Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
    Oral Oncol. 2025;168:107591.
    >> Share

  146. LAVANYA K, Sathishkumar K, Nallusamy D
    Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107590.
    >> Share

  147. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
    Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;168:107585.
    >> Share

  148. KOKER G, Ozcelik G
    Comment on: "Cisplatin ototoxicity and hydration schedules''.
    Oral Oncol. 2025;168:107545.
    >> Share

  149. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
    Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
    Oral Oncol. 2025;168:107556.
    >> Share

  150. SUDARSON J
    Commentary on "molecular features of T and N stage progression in laryngeal cancer".
    Oral Oncol. 2025;168:107587.
    >> Share

  151. YU Z, Zhuang Z, Zhao X, Chi H, et al
    Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
    Oral Oncol. 2025;168:107586.
    >> Share

  152. ASHOKKUMAR K
    Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107580.
    >> Share

  153. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
    Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
    Oral Oncol. 2025;168:107575.
    >> Share

  154. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
    Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
    Oral Oncol. 2025;168:107577.
    >> Share

  155. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
    Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
    Oral Oncol. 2025;167:107466.
    >> Share

  156. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
    Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
    Oral Oncol. 2025;167:107438.
    >> Share

  157. SEDASSARI BT, Celin MF, Pigatti FM
    SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
    Oral Oncol. 2025;167:107435.
    >> Share

  158. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
    Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
    Oral Oncol. 2025;167:107431.
    >> Share

  159. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
    Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;167:107429.
    >> Share

  160. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
    Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
    Oral Oncol. 2025;167:107384.
    >> Share

  161. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
    Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
    Oral Oncol. 2025;167:107405.
    >> Share

  162. TONG JY, Brimanson K, Moyer K, Wolf J, et al
    Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
    Oral Oncol. 2025;167:107403.
    >> Share

  163. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
    Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
    Oral Oncol. 2025;168:107544.
    >> Share

  164. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
    Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;168:107571.
    >> Share

  165. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
    Social health at 5 years after diagnosis of head and neck cancer.
    Oral Oncol. 2025;168:107567.
    >> Share

    July 2025
  166. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
    Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
    Oral Oncol. 2025;168:107536.
    >> Share

  167. LI Y, Xiao L, Xie R
    Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
    Oral Oncol. 2025;168:107549.
    >> Share

  168. SHARFUNNISA SH
    Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
    Oral Oncol. 2025;168:107563.
    >> Share

  169. ZHANG D, Cai M
    Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107558.
    >> Share

  170. RAJASEKAR A
    Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
    Oral Oncol. 2025;168:107561.
    >> Share

  171. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    >> Share

  172. KRISHNAN M, Babu S
    Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
    Oral Oncol. 2025;168:107546.
    >> Share

  173. PENG J, Liang Z, Wang J, Wang G, et al
    Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107537.
    >> Share

  174. KRISHNAN M, Babu S
    Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
    Oral Oncol. 2025;168:107562.
    >> Share

  175. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    >> Share

  176. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
    Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
    Oral Oncol. 2025;168:107512.
    >> Share

  177. BABU S, Krishnan M, Ravi PS
    "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
    Oral Oncol. 2025;168:107552.
    >> Share

  178. KRISHNAN M, Chawla KK, Babu S, D S, et al
    Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
    Oral Oncol. 2025;168:107543.
    >> Share

  179. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
    The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
    Oral Oncol. 2025;168:107548.
    >> Share

  180. ARULMOORTHY MP
    Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
    Oral Oncol. 2025;168:107518.
    >> Share

  181. SHARFUNNISA SH, Rahmathullah A
    Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
    Oral Oncol. 2025;168:107539.
    >> Share

  182. BABU S, Solomon A, Krishnan M
    Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
    Oral Oncol. 2025;168:107528.
    >> Share

  183. JEYARAJ G
    Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107532.
    >> Share

  184. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    >> Share

  185. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    >> Share

  186. ZHU J, Xu J, Qu H, Hao J, et al
    A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107511.
    >> Share

  187. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
    Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107467.
    >> Share

  188. YANG Z, Lin B, Xie R
    Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
    Oral Oncol. 2025;167:107490.
    >> Share

  189. ZHANG Y, Liang R, Lai P
    Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;167:107491.
    >> Share

  190. JEYARAJ G
    Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
    Oral Oncol. 2025;167:107487.
    >> Share

  191. RAJATHIRAJAN SD
    Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
    Oral Oncol. 2025;167:107483.
    >> Share

  192. JEYARAJ G
    Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
    Oral Oncol. 2025;167:107488.
    >> Share

  193. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
    Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
    >> Share

  194. RAJATHIRAJAN SD
    Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
    Oral Oncol. 2025;167:107472.
    >> Share

  195. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    >> Share

  196. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    >> Share

  197. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    >> Share

  198. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    >> Share

    June 2025
  199. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    >> Share

  200. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    >> Share

  201. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    >> Share

  202. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    >> Share

  203. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
    Oral Oncol. 2025;167:107456.
    >> Share

  204. DAUNGSUPAWONG H, Wiwanitkit V
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
    Oral Oncol. 2025;167:107454.
    >> Share

  205. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
    Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
    Oral Oncol. 2025;167:107439.
    >> Share

  206. NGO DQ, Truong DS, Le DT, Hoang TM, et al
    Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
    Oral Oncol. 2025;167:107406.
    >> Share

  207. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    >> Share

  208. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
    Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
    Oral Oncol. 2025;167:107337.
    >> Share

  209. MAK CH, Cao LM, Luo HY, Zhou K, et al
    Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107430.
    >> Share

  210. YANG X, Li R
    Reconsidering the prognostic value of HRQOL in head and neck cancer.
    Oral Oncol. 2025;167:107421.
    >> Share

  211. YAN Y, Wang Z, Sun Y
    Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
    Oral Oncol. 2025;167:107427.
    >> Share

  212. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
    Oral Oncol. 2025;167:107404.
    >> Share

  213. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
    Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
    Oral Oncol. 2025;165:107342.
    >> Share

  214. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
    Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;165:107330.
    >> Share

  215. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    >> Share

  216. JANG HB, Lee DH, Lim SC
    Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
    Oral Oncol. 2025;165:107317.
    >> Share

  217. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
    Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
    Oral Oncol. 2025;165:107310.
    >> Share

    May 2025
  218. HINTZE JM, Cleere E, Soo A, Timon C, et al
    Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
    Oral Oncol. 2025;167:107402.
    >> Share

  219. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
    Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
    Oral Oncol. 2025;166:107387.
    >> Share

  220. JEYARAJ G
    Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;166:107401.
    >> Share

  221. LIU X, Xue S
    Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2025;166:107368.
    >> Share

  222. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
    The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
    Oral Oncol. 2025;166:107367.
    >> Share

  223. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    >> Share

  224. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
    Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
    Oral Oncol. 2025;166:107363.
    >> Share

  225. MALI SB
    Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
    Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
    >> Share

  226. MALI SB
    Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
    Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
    >> Share

  227. SHAIKH N, Pandey M, Manna S, Gawde J, et al
    Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
    Oral Oncol. 2025;165:107346.
    >> Share

  228. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    >> Share

  229. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
    Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
    Oral Oncol. 2025;165:107351.
    >> Share

  230. ZHU X, Xu H, Zhao Y, Diao W, et al
    Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
    Oral Oncol. 2025;165:107347.
    >> Share

  231. PEI Y, Yang Z, Mao Y, Chen X, et al
    Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
    Oral Oncol. 2025;165:107333.
    >> Share

  232. XIAO X, Liu T, Lu M, Song Z, et al
    Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107344.
    >> Share

  233. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    >> Share

  234. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
    Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
    Oral Oncol. 2025;164:107264.
    >> Share

  235. CANALI L, Russo E, Pangallo S, Bussu F, et al
    Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2025;164:107270.
    >> Share

  236. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
    Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
    Oral Oncol. 2025;164:107260.
    >> Share

  237. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    >> Share

    April 2025
  238. MALI SB
    Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
    Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
    >> Share

  239. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    >> Share

  240. SILVA CUNHA JL
    Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;165:107336.
    >> Share

  241. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    >> Share

  242. ARDILA CM
    Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
    Oral Oncol. 2025;165:107303.
    >> Share

  243. JEYARAJ G
    Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
    Oral Oncol. 2025;165:107331.
    >> Share

  244. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
    Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
    Oral Oncol. 2025;165:107299.
    >> Share

  245. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
    Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
    Oral Oncol. 2025;165:107304.
    >> Share

  246. JEYARA G
    Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
    Oral Oncol. 2025;165:107320.
    >> Share

  247. ZHOU P, Zhu Y, Xu B, Jiang X, et al
    Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
    Oral Oncol. 2025;165:107316.
    >> Share

  248. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    >> Share

  249. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
    Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107287.
    >> Share

  250. JEYARAJ G
    Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
    Oral Oncol. 2025;165:107302.
    >> Share

  251. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
    Molecular features of T and N stage progression in laryngeal cancer.
    Oral Oncol. 2025;165:107283.
    >> Share

  252. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
    Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
    Oral Oncol. 2025;164:107246.
    >> Share

  253. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
    Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
    >> Share

  254. MA J, Brooks C, Tasoulas J, Wind LS, et al
    Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;164:107293.
    >> Share

  255. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
    Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
    Oral Oncol. 2025;164:107290.
    >> Share

  256. XIAO J, You M, Song Y, Gao R, et al
    Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
    Oral Oncol. 2025;164:107288.
    >> Share

  257. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
    Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
    Oral Oncol. 2025;164:107266.
    >> Share

  258. JEYARAJ G
    Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
    Oral Oncol. 2025;164:107285.
    >> Share

  259. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    >> Share

    March 2025
  260. LIN N, Zhou X, Wang Y, Zhou J, et al
    Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
    Oral Oncol. 2025;164:107269.
    >> Share

  261. JEYARAJ G
    Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
    Oral Oncol. 2025;163:107256.
    >> Share

  262. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    >> Share

  263. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
    Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
    Oral Oncol. 2025;163:107250.
    >> Share

  264. DONG Z, Wang GY, Qin GJ, Dai DY, et al
    Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
    Oral Oncol. 2025;163:107223.
    >> Share

  265. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    >> Share

  266. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
    Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;163:107248.
    >> Share

  267. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    >> Share

  268. GAZZINI L, Festa BM, Calabrese L
    Elective neck dissection: Are we bound to outdated concepts?
    Oral Oncol. 2025;163:107245.
    >> Share

  269. WU WJ, An PG, Liu Q, Zhang ZQ, et al
    Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
    Oral Oncol. 2025;162:107218.
    >> Share

  270. YANG F, Peng W, Wei H, Li X, et al
    Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
    Oral Oncol. 2025;162:107187.
    >> Share

  271. YE Z, Li X, Xie F, Sun J, et al
    A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
    Oral Oncol. 2025;162:107185.
    >> Share

  272. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
    Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2025;162:107180.
    >> Share

  273. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
    Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
    Oral Oncol. 2025;163:107224.
    >> Share

  274. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
    Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
    Oral Oncol. 2025;163:107228.
    >> Share

    February 2025
  275. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
    Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
    Oral Oncol. 2025;163:107227.
    >> Share

  276. JEYARAJ G
    Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
    Oral Oncol. 2025;163:107231.
    >> Share

  277. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
    Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
    Oral Oncol. 2025;162:107220.
    >> Share

  278. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
    Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
    Oral Oncol. 2025;162:107219.
    >> Share

  279. YANG H, Sun P, Wang Y, Wang X, et al
    Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
    Oral Oncol. 2025;162:107211.
    >> Share

  280. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    >> Share

  281. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    >> Share

  282. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    >> Share

  283. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    >> Share

  284. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    >> Share

  285. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    >> Share

  286. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    >> Share

  287. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    >> Share

  288. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    >> Share

    January 2025
  289. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    >> Share

  290. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    >> Share

  291. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    >> Share

  292. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    >> Share

  293. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    >> Share

  294. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    >> Share

  295. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    >> Share

  296. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    >> Share

  297. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    >> Share

  298. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    >> Share

  299. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    >> Share

  300. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    >> Share

    December 2024
  301. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    >> Share

  302. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    >> Share

  303. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    >> Share

  304. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    >> Share

  305. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    >> Share

  306. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    >> Share

  307. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    >> Share

  308. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    >> Share

  309. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    >> Share

  310. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    >> Share

  311. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    >> Share

  312. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    >> Share

  313. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    >> Share

  314. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    >> Share

  315. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    >> Share

  316. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    >> Share

  317. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    >> Share

  318. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    >> Share

  319. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    >> Share

  320. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    >> Share

  321. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    >> Share

  322. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    >> Share

  323. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    >> Share

    November 2024
  324. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    >> Share

  325. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    >> Share

  326. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    >> Share

  327. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    >> Share

  328. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    >> Share

  329. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    >> Share

  330. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    >> Share

  331. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    >> Share

  332. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    >> Share

  333. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    >> Share

  334. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    >> Share

  335. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    >> Share

  336. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    >> Share

  337. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    >> Share

  338. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    >> Share

  339. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    >> Share

  340. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    >> Share

  341. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    >> Share

    October 2024
  342. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    >> Share

  343. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    >> Share

  344. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    >> Share

  345. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    >> Share

  346. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    >> Share

  347. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    >> Share

  348. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    >> Share

  349. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    >> Share

  350. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    >> Share

  351. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    >> Share

  352. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    >> Share

  353. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    >> Share

  354. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    >> Share

  355. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    >> Share

  356. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    >> Share

  357. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    >> Share

  358. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    >> Share

  359. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    >> Share

  360. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    >> Share

    September 2024
  361. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    >> Share

  362. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    >> Share

  363. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    >> Share

  364. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    >> Share

  365. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    >> Share

  366. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    >> Share

  367. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    >> Share

  368. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    >> Share

  369. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    >> Share

  370. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    >> Share

  371. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    >> Share

  372. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    >> Share

  373. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    >> Share

  374. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    >> Share

  375. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    >> Share

  376. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    >> Share

  377. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    >> Share

  378. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    >> Share

  379. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    >> Share

    August 2024
  380. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    >> Share

  381. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    >> Share

  382. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    >> Share

  383. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    >> Share

  384. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    >> Share

  385. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    >> Share

  386. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    >> Share

  387. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    >> Share

  388. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    >> Share

  389. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    >> Share

  390. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    >> Share

  391. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    >> Share

  392. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    >> Share

  393. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    >> Share

  394. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    >> Share

  395. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    >> Share

  396. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    >> Share

  397. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    >> Share

  398. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    >> Share

  399. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    >> Share

  400. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    >> Share

    July 2024
  401. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    >> Share

  402. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    >> Share

  403. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    >> Share

  404. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    >> Share

  405. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    >> Share

  406. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    >> Share

  407. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    >> Share

  408. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    >> Share

  409. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    >> Share

  410. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    >> Share

  411. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    >> Share

  412. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    >> Share

  413. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    >> Share

  414. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    >> Share

  415. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    >> Share

  416. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    >> Share

  417. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    >> Share

  418. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    >> Share

  419. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    >> Share

  420. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    >> Share

  421. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    >> Share

  422. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    >> Share

  423. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    >> Share

  424. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    >> Share

  425. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    >> Share

  426. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    >> Share

  427. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    >> Share

  428. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    >> Share

  429. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    >> Share

  430. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    >> Share

    June 2024
  431. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    >> Share

  432. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    >> Share

  433. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    >> Share

  434. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    >> Share

  435. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    >> Share

  436. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    >> Share

  437. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    >> Share

  438. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    >> Share

  439. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    >> Share

  440. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    >> Share

  441. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    >> Share

  442. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    >> Share

  443. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    >> Share

  444. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    >> Share

  445. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    >> Share

  446. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    >> Share

  447. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    >> Share

  448. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    >> Share

  449. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    >> Share

  450. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    >> Share

  451. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    >> Share

  452. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    >> Share

  453. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    >> Share

  454. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    >> Share

  455. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    >> Share

  456. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    >> Share

    May 2024
  457. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    >> Share

  458. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    >> Share

  459. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    >> Share

  460. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    >> Share

  461. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    >> Share

  462. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    >> Share

  463. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    >> Share

  464. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    >> Share

  465. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    >> Share

  466. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    >> Share

  467. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    >> Share

  468. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    >> Share

  469. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    >> Share

  470. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    >> Share

  471. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    >> Share

  472. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    >> Share

  473. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    >> Share

  474. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    >> Share

  475. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    >> Share

  476. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    >> Share

  477. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    >> Share

  478. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    >> Share

  479. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    >> Share

  480. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    >> Share

    April 2024
  481. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    >> Share

  482. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    >> Share

  483. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    >> Share

  484. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    >> Share

  485. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    >> Share

  486. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    >> Share

  487. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    >> Share

  488. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    >> Share

  489. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    >> Share

  490. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    >> Share

  491. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    >> Share

  492. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    >> Share

  493. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    >> Share

  494. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    >> Share

  495. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    >> Share

  496. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    >> Share

  497. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    >> Share

  498. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    >> Share

  499. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    >> Share

  500. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    >> Share

  501. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    >> Share

    March 2024
  502. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    >> Share

  503. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    >> Share

  504. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    >> Share

  505. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    >> Share

  506. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    >> Share

  507. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    >> Share

  508. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    >> Share

  509. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    >> Share

  510. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    >> Share

  511. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    >> Share

  512. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    >> Share

  513. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    >> Share

  514. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    >> Share

  515. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    >> Share

  516. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    >> Share

  517. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    >> Share

  518. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    >> Share

  519. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    >> Share

    February 2024
  520. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    >> Share

  521. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    >> Share

  522. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016